NASDAQ
09.04.26 | 21:59
2,825 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:59 | Roche places a $1bn bet on C4T degrader-antibody conjugates | 3 | pharmaphorum | ||
| 11:46 | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 3 | Pharmaceutical Technology | ||
| 11:10 | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 14 | transkript.de | ||
| Do | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 13 | Benzinga.com | ||
| Do | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| Do | C4 Therapeutics Enters Collaboration Agreement With Roche | 289 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Roche und C4 Therapeutics erweitern Forschungszusammenarbeit | 9 | cash | ||
| Do | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com | ||
| Do | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | 275 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 25.03. | Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock | 2 | Insider Monkey | ||
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.02. | Barclays raises C4 Therapeutics stock price target on trial progress | 9 | Investing.com | ||
| 26.02. | TD Cowen reiterates Buy rating on C4 Therapeutics stock | 1 | Investing.com | ||
| 26.02. | TD Cowen bestätigt "Buy"-Rating für C4 Therapeutics nach starkem Kursanstieg | 2 | Investing.com Deutsch | ||
| 26.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 26.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.02. | C4 Therapeutics beats Q4 street views | 1 | Seeking Alpha | ||
| 26.02. | Earnings Summary: C4 Therapeutics Q4 | 1 | Benzinga.com | ||
| 26.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,626 | +0,87 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,930 | +2,14 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| CELLDEX THERAPEUTICS | 28,400 | -1,15 % | Celldex closes $345 million stock offering | ||
| CARDIFF ONCOLOGY | 1,384 | -3,89 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,453 | +2,69 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,225 | 0,00 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| NEOVACS | 0,001 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| GYRE THERAPEUTICS | 6,150 | 0,00 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen... ► Artikel lesen | |
| ULTRAGENYX | 20,230 | -1,03 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) | If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 4,740 | -1,66 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026... ► Artikel lesen | |
| GOSSAMER BIO | 0,311 | -2,81 % | Gossamer Bio, Inc. - 8-K, Current Report | ||
| BIOMEA FUSION | 1,850 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies | COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline... ► Artikel lesen | |
| JANUX THERAPEUTICS | 14,520 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SOLID BIOSCIENCES | 8,090 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | - Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,733 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,825 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.